HITTING A MOVING TARGET
By Holge Hannemann, Director of Research, The Native Antigen Company Influenza viruses A and B are a major public health concern, mainly affecting the pharynx, trachea, and sometimes the lungs of millions of people worldwide each year, with symptoms that range from...
Influenza antigens for Northern Hemisphere’s 2023-2024 flu season
Most recent figures published by UK Health Security Agency show that the 2022/2023 Influenza season has been worse than any of the past surveillance periods (GOV.UK, 2023), see Figure 1 (below). High level of Influenza incidence increased the burden on the National...
Bacterial Antigens, Antibodies, and custom solutions for your research needs
Group A Streptococcus infections on the rise The unusually high incidence of Invasive Group A Streptococcus disease (GAS), especially dangerous for children and immunocompromised adults, dominated media stories this winter. According to the UK governmental data...
The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein
Antigen designed to support immunoassay and vaccine development applications Oxford, UK, XX December 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and...
The Native Antigen Company introduces new range of influenza antigens
Season-specific Haemagglutinin and Neuraminidase antigens will support vaccine and diagnostic reformulation programmes New range developed to cover 2023 southern hemisphere flu season Oxford, UK, 14 November 2022: The Native Antigen Company (part of LGC Clinical...
The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant
New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...
The Native Antigen Company will be exhibiting at MEDICA
The Native Antigen Company will be exhibiting at MEDICA in Dϋsseldorf, Germany, 14-17 November at Hall 3 Booth 3H42 as part of the LGC Clinical Diagnostics Group. Please come and speak with one of our Experts at our booth. In line with the theme of this year’s event,...
Opening of a new state-of-the-art site in Oxford will deliver critical diagnostics solutions and research
About The Native Antigen Company From its humble beginnings in 2010, The Native Antigen Company has become one of the world’s leading suppliers of reagents, that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases. We...
The Native Antigen Company (Part of LGC Clinical Diagnostics) has moved to a new state-of-the-art site in Oxford, delivering critical diagnostics solutions and research.
Left to Right: Euan O’Sullivan (President and Chief Executive Officer LGC Group), Dame Sarah Gilbert DBE , Mark Dearden (Managing Director, LGC Biosearch Technologies) Teresa Lambe OBE, Nicholas Roesen, (COO The Native Antigen Company), Bharathi Anekella...
Monkeypox; 3 months on
It has been 3 months since a new, unusually widespread outbreak of Monkeypox was first identified. What was normally a virus confined to limited infections in the West African continent is becoming a global health concern. What have we learned about this virus...
COVID-19 Underlines the Need for Universal Vaccines
This article was originally published on Clinical Lab Manager. In recent history, humanity has witnessed numerous emerging viral diseases, including the SARS, MERS, and SARS-2 coronaviruses, as well as HIV, Zika, Ebola, and H1N1 and H3N2 influenza. None have tested...
Tick-Borne Diseases: The Need for Integrated Approaches to Human-Animal Diagnosis
This article has been published in Volume 8, Issue 3 of International Animal Health Journal. Ticks are responsible for a diverse group of neglected, and rapidly expanding diseases, affecting humans, companion animals and livestock. A growing understanding of tick-host...
The Continued Challenges of Flavivirus Serology
This article was originally published on the Science Advisory Board. Flaviviruses are a genus of positive-sense RNA viruses, largely transmitted by mosquito and tick vectors that cause infections, including yellow fever, dengue, the Zika virus, West Nile virus,...
The Role of Serology in Tracking COVID-19 Mutations
This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...
Preparing for Disease Y: A Better Serological Toolbox
This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...
Keeping Up with the New SARS-CoV-2 Variant Nomenclature
If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...
Making Sense of the SARS-CoV-2 Spike Mutations
Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...
D614G: Putting the Mutation in Perspective
Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...
Lyme Disease: A Rapidly Emerging Bacterial Infection in Need of New Diagnostics
This article was first published on Clinical Lab Products. Lyme disease is now the most common and fastest growing vector-borne illness in the Western world. A two-tiered antibody testing approach is currently used for clinical diagnosis, but suffers from several...
The Yearly Race for an Influenza Vaccine and the Role of Reagents
In this blog, we explain how seasonal and pandemic influenza vaccines are developed, manufactured and validated, and introduce our contract services for the rapid development of custom influenza reagents. The Influenza Viruses: A Quick Recap The influenza viruses are...
The Endemic Coronaviruses and What They Might Tell us About COVID-19
While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...
Q&A: An Insight Into COVID-19 Serology
During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...
A Q&A with David Flavell of Leukaemia Busters
In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research. Tell me about your scientific background David. I was born in a seaside town called Southport in...